Thermo Fisher Scientific supplies instruments, laboratory consumables, diagnostics, and outsourced life-sciences services. Its portfolio includes mass spectrometry, chromatography, analytical equipment, laboratory supplies, clinical research services through PPD, and biopharmaceutical production capabilities. It serves pharmaceutical developers, academic researchers, hospitals, and industrial labs through equipment sales, recurring consumables, and contracted services.
Thermo Fisher Scientific Inc. (TMO) has a MarketKingdoms composite score of 67.2 (B), an B-range rating. It ranks 578th of 1,866 covered companies, 27th of 78 in Healthcare (sector average 64.5) and 10th of 13 in Diagnostics & Research. Scores as of 2026-10-25.
Its strongest lenses are Industry opportunity at 90 (Healthcare average 81) and KPI momentum at 82 (Healthcare average 78). Its weakest lenses are Price (valuation) at 33 (sector average 50) and Quality (profitability) at 41 (sector average 50).
| Lens | Type | TMO | Healthcare average | Diagnostics & Research average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 90 | 81 | 90 | 95th |
| Stock selection | Research signal | 79 | 79 | 83 | 44th |
| KPI momentum | Research signal | 82 | 78 | 85 | 60th |
| Catalyst watch | Research signal | 78 | 74 | 77 | 76th |
| Price (valuation) | Fundamental lens | 33 | 50 | 32 | 31st |
| Expansion (growth) | Fundamental lens | 47 | 50 | 52 | 51st |
| Quality (profitability) | Fundamental lens | 41 | 50 | 42 | 38th |
| Trend (momentum) | Fundamental lens | 65 | 50 | 69 | 67th |
The most recent call analysed was held on 2026-10-21 (fiscal 2026 Q3). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -11.9%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta 0.51, sector beta -0.09, industry beta 1.06; the factor model explains 71% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Illumina Inc. (ILMN) | 71.0 | B+ | +22.1% |
| Quest Diagnostics Incorporated (DGX) | 69.4 | B | -4.1% |
| Agilent Technologies Inc. (A) | 69.2 | B | -3.1% |
| Revvity Inc. (RVTY) | 69.2 | B | +8.2% |
| IQVIA Holdings Inc. (IQV) | 68.8 | B | -16.5% |
| Labcorp Holdings Inc. (LH) | 68.8 | B | -13.5% |
| Natera Inc. (NTRA) | 68.5 | B | -22.9% |
| Charles River Laboratories International Inc. (CRL) | 68.0 | B | -15.8% |
Thermo Fisher Scientific Inc. financial statements · Healthcare sector ranking · Diagnostics & Research industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.